Published in AIDS on September 12, 2008
Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc (2013) 1.09
High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatr (2012) 1.08
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis (2016) 0.94
Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men. Pharmacogenet Genomics (2011) 0.88
DNA methylation patterns are associated with n-3 fatty acid intake in Yup'ik people. J Nutr (2014) 0.88
Ageing and inflammation in patients with HIV infection. Clin Exp Immunol (2016) 0.86
Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study. Int J Mol Sci (2014) 0.84
New and emerging agents in the management of lipodystrophy in HIV-infected patients. HIV AIDS (Auckl) (2010) 0.83
Effects of PPARγ and RBP4 gene variants on metabolic syndrome in HIV-infected patients with anti-retroviral therapy. PLoS One (2012) 0.81
Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients. AIDS Res Hum Retroviruses (2012) 0.80
The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children. J Int AIDS Soc (2015) 0.79
Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism. BMC Med Genet (2011) 0.78
Biceps skin-fold thickness may detect and predict early lipoatrophy in HIV-infected children. Pediatr Infect Dis J (2013) 0.77
Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients. Antimicrob Agents Chemother (2014) 0.76
Association of immune recovery with hyperlipidaemia and apolipoprotein gene polymorphisms following highly active antiretroviral therapy in a cohort of Chinese HIV patients. BMJ Open (2016) 0.75
Getting to 90-90-90 in paediatric HIV: What is needed? J Int AIDS Soc (2015) 0.75
Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. World J Virol (2015) 0.75
Genome-Wide Association Study of HIV-Related Lipoatrophy in Thai Patients: Association of a DLGAP1 Polymorphism with Fat Loss. AIDS Res Hum Retroviruses (2015) 0.75
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet (2006) 5.19
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59
Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr (2007) 3.40
OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain (2007) 3.35
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain (2008) 2.57
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS (2011) 2.45
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med (2002) 2.20
Data analysis in flow cytometry: the future just started. Cytometry A (2010) 2.18
The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS (2009) 2.15
Digging for innate immunity since Darwin and Metchnikoff. Bioessays (2002) 2.13
Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics (2004) 1.98
Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr (2002) 1.97
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis (2009) 1.95
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol (2008) 1.90
Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood (2012) 1.89
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV (2015) 1.85
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence (2010) 1.84
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin Infect Dis (2008) 1.74
The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther (2007) 1.71
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis (2011) 1.68
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med (2010) 1.65
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 1.60
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis (2011) 1.57
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis (2010) 1.54
Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine (2007) 1.53
Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis (2002) 1.52
Biological importance of the two Toll-like receptors, TLR2 and TLR4, in macrophage response to infection with Candida albicans. FEMS Immunol Med Microbiol (2005) 1.50
Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest (2009) 1.49
Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med (2011) 1.49
Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr (2008) 1.47
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol (2015) 1.45
Induction of mitochondrial biogenesis is a maladaptive mechanism in mitochondrial cardiomyopathies. J Am Coll Cardiol (2007) 1.43
Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol (2012) 1.41
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. AIDS (2003) 1.41
Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis (2004) 1.40
Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS (2006) 1.40
Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc (2007) 1.38
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS (2004) 1.37
Resolution of multidrug-refractory oesophageal candidiasis in an AIDS patient after treatment with caspofungin. AIDS (2002) 1.37
IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol (2007) 1.35
Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry A (2005) 1.35
Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis (2007) 1.33
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: evidence from the Italian cohort of antiretroviral-naive patients study. J Acquir Immune Defic Syndr (2006) 1.31
Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther (2011) 1.30
Subject classification obtained by cluster analysis and principal component analysis applied to flow cytometric data. Cytometry A (2007) 1.28
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr (2006) 1.27
Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther (2003) 1.26
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev (2011) 1.26
Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry. Nat Protoc (2009) 1.25
Early changes in intramitochondrial cardiolipin distribution during apoptosis. Cell Growth Differ (2002) 1.25
Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr (2003) 1.25
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis (2014) 1.25
The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol (2003) 1.23
Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.23
Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother (2011) 1.22
Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis (2002) 1.17
Cytotoxic granule release dominates gag-specific CD4+ T-cell response in different phases of HIV infection. AIDS (2010) 1.16
Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther (2005) 1.14
Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin. Cancers (Basel) (2010) 1.14
Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr (2003) 1.13
Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS (2003) 1.13
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13